相关实验视频

Updated: Sep 9, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

在急性骨髓性白血病中通过联合泛HDAC和CDK抑制的TP53无关死亡率

Aurélien Pottier¹, Sujung Park², Yejin Lee²

¹Laboratoire de Biologie Moléculaire et Cellulaire du Cancer (LBMCC), 6A rue Nicolas-Ernest Barblé, L-1210, Luxembourg.

|September 3, 2025

概括

使用迪纳西克利布和CAY10603同时抑制循环依赖激酶 (CDK) 和基因脱甲基酶 (HDAC) 有效治疗TP53突变急性髓性白血病 (AML). 这种组合疗法使治疗反应正常化,并提供了一个有前途的TP53无关治疗选择.

科学领域:

血液学
分子生物学
癌症学

背景情况:

有TP53突变的急性髓性白血病 (AML) 预后不佳,且迅速抗治疗.
现有疗法显示TP53突变型和野生型AML之间的治疗反应差距.

研究的目的:

在TP53突变AML中研究CDK和HDAC联合抑制的疗效.
评估一种针对细胞周期和转录途径的新疗法.

主要方法:

在临床前的AML模型中使用了dinaciclib (CDK抑制剂) 和CAY10603 (HDAC抑制剂).
进行生物化学分析,评估克隆生长,细胞亡和关键蛋白调节.
评估了在正体NSG小鼠模型中的组合疗法.

主要成果:

组合治疗消除了TP53突变型和野生型AML之间的响应差距.
CAY10603既具有HDAC6选择性,也具有泛HDAC活性.
联合治疗抑制了白血病的生长,诱导了细胞亡,并恢复了CDKN1A/ p21水平.
在没有毒性的小鼠中,dinaciclib + CAY10603 降低了白血病负担和延长了生存期.

结论:

双重抑制CDK和HDAC为AML提供了TP53无关的治疗策略.
这种组合使TP53突变AML反应正常化,表明临床潜力.
需要对这种泛HDAC/多CDK阻断进行进一步的临床评估.

关键词:

其他:细胞周期检查点迪纳西克利表观遗传学 MYC的信号美国没有.

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...